Europe Ovarian Cancer Diagnostics And Therapeutics Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The market covers the full clinical pathway for ovarian cancer in Europe, from diagnostic modalities such as transvaginal ultrasound, CA-125 blood testing, CT and MRI imaging, and emerging molecular biomarker assays, through to therapeutics including surgery, platinum-based chemotherapy, anti-angiogenic agents and PARP inhibitors. Public reimbursement through national health systems and growing private insurance coverage underpin routine adoption of these products. Demand is concentrated in Western Europe, with Germany, the UK, France, Italy and Spain representing the largest national markets.

• •Diagnostics account for the larger share of current spending, while therapeutics is the faster-growing segment due to high drug prices.
• •Western Europe dominates regional revenue, while Central and Eastern Europe show the strongest growth rates.
• •Hospital-based oncology centers and specialized gynecology clinics are the primary end-users.

Aging populations across the continent are expanding the at-risk cohort, with most cases diagnosed in women over 50, pushing up demand for both screening-adjacent diagnostics and treatment capacity. Advances in biomarker discovery, particularly BRCA1/2 and homologous recombination deficiency testing, are enabling more personalized therapeutic decisions and supporting uptake of targeted drugs. Regulatory streamlining by the European Medicines Agency and national HTA bodies has shortened timelines for novel therapies to reach patients.

• •Rising ovarian cancer incidence and improved survival are increasing the treated patient pool each year.
• •Genetic testing penetration is rising rapidly as BRCA and HRD tests become standard at diagnosis.
• •EMA approvals of new targeted therapies, including additional PARP inhibitors and antibody-drug conjugates, are expanding the treatment arsenal.

By product type, the market splits between diagnostics (imaging, blood-based biomarkers, genetic tests, biopsies) and therapeutics (chemotherapy, targeted therapy, hormonal therapy, immunotherapy). By cancer type, epithelial ovarian tumors represent the dominant share, with germ cell and stromal cell tumors forming smaller niches. Geographically, the UK, Germany, France and Italy lead in revenue, while Poland, the Czech Republic and the Nordics are emerging as growth markets supported by EU-funded cancer plans.

• •Diagnostics is segmented into imaging, blood markers, genetic and other tests; therapeutics into chemo, targeted, hormonal and immunotherapy.
• •Epithelial ovarian cancer accounts for the majority of cases and therapeutic spending.
• •Germany and the UK together represent the single largest sub-regional bloc by revenue.

What are the recent trends and outlook?

Liquid biopsy and multi-cancer early detection programs are gaining traction in research consortia and could shift the diagnostics mix later in the decade. Combination regimens pairing PARP inhibitors with anti-angiogenic agents or immunotherapy are entering routine practice and reshaping the therapeutics segment. EU Beating Cancer Plan funding and national cancer strategies are expected to keep screening and genetic counseling capacity expanding through 2030 and beyond.

• •Liquid biopsy and ctDNA-based monitoring are moving from research into early clinical adoption.
• •PARP inhibitor combinations and antibody-drug conjugates are reshaping first- and second-line treatment standards.
• •EU and national cancer plans are likely to sustain near double-digit annual market growth through the forecast horizon.